Selected research
Industry Research
Orexin Receptor Type 2 Industry Research Report 2026
Market perspective
The global Orexin Receptor Type 2 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Orexin Receptor Type 2 market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Orexin Receptor Type 2 market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Orexin Receptor Type 2 market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Orexin Receptor Type 2 include Yangtze River Pharmaceutical Group, Eisai Co Ltd, Johnson & Johnson, Merck & Co Inc, OptiNose US Inc, Idorsia Ltd, Heptares Therapeutics Ltd, Evotec AG and Actelion Pharmaceuticals Ltd. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Orexin Receptor Type 2 market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Orexin Receptor Type 2.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Orexin Receptor Type 2 Market by Company
Yangtze River Pharmaceutical Group
Eisai Co Ltd
Johnson & Johnson
Merck & Co Inc
OptiNose US Inc
Idorsia Ltd
Heptares Therapeutics Ltd
Evotec AG
Actelion Pharmaceuticals Ltd
Orexin Receptor Type 2 Segment by Type
HTL-6641
MK-8133
OPN-021
YNT-185
Lemborexant
Others
Orexin Receptor Type 2 Segment by Application
Major Depressive Disorder
Sleep Disorders
Narcolepsy
Insomnia
Orexin Receptor Type 2 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orexin Receptor Type 2 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Orexin Receptor Type 2 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orexin Receptor Type 2.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Orexin Receptor Type 2 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- HTL-6641
- MK-8133
- OPN-021
- YNT-185
- Lemborexant
- Others
Applications
- Major Depressive Disorder
- Sleep Disorders
- Narcolepsy
- Insomnia
Companies covered
- Yangtze River Pharmaceutical Group
- Eisai Co Ltd
- Johnson & Johnson
- Merck & Co Inc
- OptiNose US Inc
- Idorsia Ltd
- Heptares Therapeutics Ltd
- Evotec AG
- Actelion Pharmaceuticals Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Orexin Receptor Type 2 by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 HTL-6641
- 2.2.3 MK-8133
- 2.2.4 OPN-021
- 2.2.5 YNT-185
- 2.2.6 Lemborexant
- 2.2.7 Others
- 2.3 Orexin Receptor Type 2 by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Major Depressive Disorder
- 2.3.3 Sleep Disorders
- 2.3.4 Narcolepsy
- 2.3.5 Insomnia
- 2.4 Assumptions and Limitations
3 Orexin Receptor Type 2 Breakdown Data by Type
- 3.1 Global Orexin Receptor Type 2 Historic Market Size by Type (2021-2026)
- 3.2 Global Orexin Receptor Type 2 Forecasted Market Size by Type (2027-2032)
4 Orexin Receptor Type 2 Breakdown Data by Application
- 4.1 Global Orexin Receptor Type 2 Historic Market Size by Application (2021-2026)
- 4.2 Global Orexin Receptor Type 2 Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Orexin Receptor Type 2 Market Perspective (2021-2032)
- 5.2 Global Orexin Receptor Type 2 Growth Trends by Region
- 5.2.1 Global Orexin Receptor Type 2 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Orexin Receptor Type 2 Historic Market Size by Region (2021-2026)
- 5.2.3 Orexin Receptor Type 2 Forecasted Market Size by Region (2027-2032)
- 5.3 Orexin Receptor Type 2 Market Dynamics
- 5.3.1 Orexin Receptor Type 2 Industry Trends
- 5.3.2 Orexin Receptor Type 2 Market Drivers
- 5.3.3 Orexin Receptor Type 2 Market Challenges
- 5.3.4 Orexin Receptor Type 2 Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Orexin Receptor Type 2 Players by Revenue
- 6.1.1 Global Top Orexin Receptor Type 2 Players by Revenue (2021-2026)
- 6.1.2 Global Orexin Receptor Type 2 Revenue Market Share by Players (2021-2026)
- 6.2 Global Orexin Receptor Type 2 Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Orexin Receptor Type 2 Head Office and Area Served
- 6.4 Global Orexin Receptor Type 2 Players, Product Type & Application
- 6.5 Global Orexin Receptor Type 2 Manufacturers Established Date
- 6.6 Global Orexin Receptor Type 2 Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Orexin Receptor Type 2 Market Size (2021-2032)
- 7.2 North America Orexin Receptor Type 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Orexin Receptor Type 2 Market Size by Country (2021-2026)
- 7.4 North America Orexin Receptor Type 2 Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Orexin Receptor Type 2 Market Size (2021-2032)
- 8.2 Europe Orexin Receptor Type 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Orexin Receptor Type 2 Market Size by Country (2021-2026)
- 8.4 Europe Orexin Receptor Type 2 Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Orexin Receptor Type 2 Market Size (2021-2032)
- 9.2 Asia-Pacific Orexin Receptor Type 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Orexin Receptor Type 2 Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Orexin Receptor Type 2 Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Orexin Receptor Type 2 Market Size (2021-2032)
- 10.2 South America Orexin Receptor Type 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Orexin Receptor Type 2 Market Size by Country (2021-2026)
- 10.4 South America Orexin Receptor Type 2 Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Orexin Receptor Type 2 Market Size (2021-2032)
- 11.2 Middle East & Africa Orexin Receptor Type 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Orexin Receptor Type 2 Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Orexin Receptor Type 2 Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Yangtze River Pharmaceutical Group
- 12.1.1 Yangtze River Pharmaceutical Group Company Information
- 12.1.2 Yangtze River Pharmaceutical Group Business Overview
- 12.1.3 Yangtze River Pharmaceutical Group Revenue in Orexin Receptor Type 2 Business (2021-2026)
- 12.1.4 Yangtze River Pharmaceutical Group Orexin Receptor Type 2 Product Portfolio
- 12.1.5 Yangtze River Pharmaceutical Group Recent Developments
- 12.2 Eisai Co Ltd
- 12.2.1 Eisai Co Ltd Company Information
- 12.2.2 Eisai Co Ltd Business Overview
- 12.2.3 Eisai Co Ltd Revenue in Orexin Receptor Type 2 Business (2021-2026)
- 12.2.4 Eisai Co Ltd Orexin Receptor Type 2 Product Portfolio
- 12.2.5 Eisai Co Ltd Recent Developments
- 12.3 Johnson & Johnson
- 12.3.1 Johnson & Johnson Company Information
- 12.3.2 Johnson & Johnson Business Overview
- 12.3.3 Johnson & Johnson Revenue in Orexin Receptor Type 2 Business (2021-2026)
- 12.3.4 Johnson & Johnson Orexin Receptor Type 2 Product Portfolio
- 12.3.5 Johnson & Johnson Recent Developments
- 12.4 Merck & Co Inc
- 12.4.1 Merck & Co Inc Company Information
- 12.4.2 Merck & Co Inc Business Overview
- 12.4.3 Merck & Co Inc Revenue in Orexin Receptor Type 2 Business (2021-2026)
- 12.4.4 Merck & Co Inc Orexin Receptor Type 2 Product Portfolio
- 12.4.5 Merck & Co Inc Recent Developments
- 12.5 OptiNose US Inc
- 12.5.1 OptiNose US Inc Company Information
- 12.5.2 OptiNose US Inc Business Overview
- 12.5.3 OptiNose US Inc Revenue in Orexin Receptor Type 2 Business (2021-2026)
- 12.5.4 OptiNose US Inc Orexin Receptor Type 2 Product Portfolio
- 12.5.5 OptiNose US Inc Recent Developments
- 12.6 Idorsia Ltd
- 12.6.1 Idorsia Ltd Company Information
- 12.6.2 Idorsia Ltd Business Overview
- 12.6.3 Idorsia Ltd Revenue in Orexin Receptor Type 2 Business (2021-2026)
- 12.6.4 Idorsia Ltd Orexin Receptor Type 2 Product Portfolio
- 12.6.5 Idorsia Ltd Recent Developments
- 12.7 Heptares Therapeutics Ltd
- 12.7.1 Heptares Therapeutics Ltd Company Information
- 12.7.2 Heptares Therapeutics Ltd Business Overview
- 12.7.3 Heptares Therapeutics Ltd Revenue in Orexin Receptor Type 2 Business (2021-2026)
- 12.7.4 Heptares Therapeutics Ltd Orexin Receptor Type 2 Product Portfolio
- 12.7.5 Heptares Therapeutics Ltd Recent Developments
- 12.8 Evotec AG
- 12.8.1 Evotec AG Company Information
- 12.8.2 Evotec AG Business Overview
- 12.8.3 Evotec AG Revenue in Orexin Receptor Type 2 Business (2021-2026)
- 12.8.4 Evotec AG Orexin Receptor Type 2 Product Portfolio
- 12.8.5 Evotec AG Recent Developments
- 12.9 Actelion Pharmaceuticals Ltd
- 12.9.1 Actelion Pharmaceuticals Ltd Company Information
- 12.9.2 Actelion Pharmaceuticals Ltd Business Overview
- 12.9.3 Actelion Pharmaceuticals Ltd Revenue in Orexin Receptor Type 2 Business (2021-2026)
- 12.9.4 Actelion Pharmaceuticals Ltd Orexin Receptor Type 2 Product Portfolio
- 12.9.5 Actelion Pharmaceuticals Ltd Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst